Infinity Pharmaceuticals | INFI - Sales Revenues


Infinity Pharmaceuticals reported $583K in Sales Revenues for its fiscal quarter ending in June of 2023.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alterity Therapeutics Limited AUD 11.38K 10.23K Dec/2022
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cipla INR 75.18B 710M Dec/2025
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 1.89M 631K Sep/2025
CSL USD 3.54B 4.68B Jun/2025
Eisai JPY 219.94B 22.58B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Grifols EUR 2.18B 37.55M Sep/2025
Incyte USD 1.51B 140M Dec/2025
Infinity Pharmaceuticals USD 583K 148K Jun/2023
Ionis Pharmaceuticals USD 157M 295M Sep/2025
J&J USD 24.6B 610M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Plus Therapeutics USD 1.31M 73K Dec/2023
Roche Holding CHF 15.65B 274.5M Dec/2025
TG Therapeutics USD 161.7M 20.6M Sep/2025